Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Lenvatinib + Letrozole|DRUG: Fulvestrant
Sponsor: National University Hospital, Singapore
Collaborators: Eisai Co., Ltd.